Literature DB >> 28778712

How I treat patients with adult onset Still's disease in clinical practice.

Marcello Govoni1, Alessandra Bortoluzzi1, Daniela Rossi2, Vittorio Modena3.   

Abstract

Adult onset Still's disease (AOSD) is a rare systemic inflammatory disease of unknown etiology characterized by four cardinal signs which are almost always present in patients: high spiking fever, arthralgia (with or without synovitis), maculo-papular salmon-pink evanescent skin rash, striking leukocytosis with neutrophilia. Here, we review the clinical features of AOSD and describe the best practice approaches for its management, reviewing available guidelines and recommendations and providing experts' insights.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2017        PMID: 28778712     DOI: 10.1016/j.autrev.2017.07.017

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  16 in total

1.  Identification of prognostic factors and construction of a nomogram for patients with relapse/refractory adult-onset Still's disease.

Authors:  Ruxue Yin; Gangjian Wang; Xiaopei Yang; Lei Zhang; Shuolin Wang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 2.980

Review 2.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

3.  Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.

Authors:  Aleksander Lenert; GYeon Oh; Michael J Ombrello; Sujin Kim
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

Review 4.  Progress in Biological Therapies for Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Sara Bindoli; Andrea Doria; Paolo Sfriso
Journal:  Biologics       Date:  2022-04-21

5.  Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity.

Authors:  Huihui Chi; Dongzhou Liu; Yue Sun; Qiongyi Hu; Honglei Liu; Xiaobing Cheng; Junna Ye; Hui Shi; Yufeng Yin; Mengru Liu; Xinyao Wu; Zhuochao Zhou; Jialin Teng; Chengde Yang; Yutong Su
Journal:  Arthritis Res Ther       Date:  2018-03-22       Impact factor: 5.156

6.  Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.

Authors:  François Vercruysse; Thomas Barnetche; Estibaliz Lazaro; Emilie Shipley; François Lifermann; Alexandre Balageas; Xavier Delbrel; Bruno Fautrel; Christophe Richez; Thierry Schaeverbeke; Marie-Elise Truchetet
Journal:  Arthritis Res Ther       Date:  2019-02-12       Impact factor: 5.156

7.  Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses.

Authors:  Jinchao Jia; Hui Shi; Mengguo Liu; Tingting Liu; Jieyu Gu; Liyan Wan; Jialin Teng; Honglei Liu; Xiaobing Cheng; Junna Ye; Yutong Su; Yue Sun; Wen Gong; Chengde Yang; Qiongyi Hu
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

8.  Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease.

Authors:  Qiongyi Hu; Hui Shi; Ting Zeng; Honglei Liu; Yutong Su; Xiaobing Cheng; Junna Ye; Yufeng Yin; Mengru Liu; Hui Zheng; Xinyao Wu; Huihui Chi; Zhuochao Zhou; Jinchao Jia; Yue Sun; Jialin Teng; Chengde Yang
Journal:  Arthritis Res Ther       Date:  2019-01-07       Impact factor: 5.156

9.  Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Chiara Baggio; Sara Bindoli; Francesca Oliviero; Paolo Sfriso
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

10.  Plasma microRNA Profiles as a Potential Biomarker in Differentiating Adult-Onset Still's Disease From Sepsis.

Authors:  Qiongyi Hu; Wen Gong; Jieyu Gu; Guannan Geng; Ting Li; Rui Tian; Zhitao Yang; Haocheng Zhang; Lingyun Shao; Tingting Liu; Liyan Wan; Jinchao Jia; Chengde Yang; Yi Shi; Hui Shi
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.